- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Kashyap Patel, MD: Preparing for Biosimilar Versus Subcutaneous Rituximab
Kashyap Patel, MD, discusses considerations for using biosimilar versus subcutaneous rituximab.
Transcript
That’s a very interesting question that you asked, because the rituximab biosimilar is very warranted and is here. The originator has come out with a new subcutaneous molecule, which probably is priced less than their own reference product in terms of [intravenous, IV]. So we are evaluating the patient convenience option first, because for the intravenous rituximab, the patient has to be in the office for about 6 to 8 hours, and the originator has another molecule that is subcutaneous, which actually could be given in 15 minutes.
The other part is, because the subcutaneous molecule is a fixed dose, it probably [average sales price, ASP] calculation-wise, may become less expensive to the healthcare system as a whole. So right now we are in a holding pattern to evaluate the time in motion, the characteristics of both molecules, and depending on what is best for the patient, depending on what improves the healthcare-related quality of life, and depending on which molecule is helping address Part B drug prices will help us make a decision. Unless and until we have the biosimilar molecule out, and it’s priced at a very competitive place, we will have to look into all of these aspects before we decide to switch over to the biosimilars.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
